Radiolabelled thymidines and deoxyuridines for measuring cellular proliferation in tumours--an update

Nuclear Medicine Communications

Volumn 23, Issue 10, 2002, Pages 925-931

  Van De Wiele, C ^a   De Bondt, P ^a   Peeters, M ^a   Vermeersch, H ^a   Dierckx, R A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYURIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; THYMIDINE; CELL DNA; DEOXYURIDINE DERIVATIVE; THYMIDINE DERIVATIVE;

CELL DIVISION; CLINICAL TRIAL; EDITORIAL; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SCINTISCANNING; AUTORADIOGRAPHY; CATABOLISM; CELL PROLIFERATION; ISOTOPE LABELING; MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; SCINTILLATION CAMERA; TUMOR CELL;

CELL DIVISION; CLINICAL TRIALS; DEOXYURIDINE; HUMANS; NEOPLASMS; PYRIMIDINES; RADIOPHARMACEUTICALS; THYMIDINE;

EID: 0036795765     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200210000-00001     Document Type: Editorial

References (49)

1. Cleaver JE. Thymidine metabolism and cell kinetics. In: Frontiers of biology, volume 6. Amsterdam: North-Holland Publishing; 1967.
2. McGilvery RW. Turnover of nucleotides. In: Biochemistry, a functional approach. Philadelphia, USA: WB Saunders Company, 1983: 674-696.
3. Mendelsohn ML. The growth fraction: a new concept applied to tumours. Science 1960; 132: 1496-1503.
4. Slingerland JM, Tannock IF. Cell proliferation and cell death. In: Tannock IF, Hill RP, eds. The basic science of oncology, 3rd edn. New York: McGraw-Hill, 1987: 134-165.
5. Fornace AJ, Fuks Z, Weichselbaum RR, Milas L. Radiation therapy. In: Mendelsohn J, Howley P, Israel M, Liotta L, eds. The molecular basis of cancer, 2nd edn. Philadelphia, USA: WB Saunders Company, 2001: 423-465.
6. Hamburger AW, Salman SE, Soehnlen B. Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 1978; 298: 1321.
7. Philips RM, Bibby MC, Double JA. Critical appraisal of the predictive value of in vitro chemosensitive assays. J Natl Cancer Inst 1990; 82: 1457.
8. Hamburger AW. in vitro evaluation of chemotherapeutic agents. Cancer Invest 1991; 9: 683.
9. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990; 31: 337-342.
10. Shields AF, Mankoff D, Graham MM, et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med 1996; 37: 290-296.
11. Mankoff DA, Shields AF, Link JM, et al. Kinetic analysis of 2-[C-11]thymidine PET imaging studies: validation studies. J Nucl Med 1999; 40: 614-624.
12. Conti PS, Hilton J, Wong DF. High-performance liquid-chromatography of C-11 labeled thymidine and its major catabolites for clinical PET studies. Nucl Med Biol 1994; 21: 1045-1051.
13. Goethals P, Sambre J, Coene M, Casteleyn K, Poupeye E. A remotely controlled production system for routine preparation of [methyl-C11]thymidine. Appl Radiat Isotop 1992; 43: 952-954.
14. Goethals P, Van Eijkeren M, Lodewyck W, Dams R. Measurement of [methyl-carbon-11]thymidine and its metabolites in head and neck tumors. J Nucl Med 1995; 36: 880-882.
15. Shields AF, Larson SM, Grunbaum Z, Graham MM. Short-term uptake in normal and neoplastic tissues: studies for PET. J Nucl Med 1984; 25: 759-764.
16. Crawford EJ, Christman D, Atkins H, Friedkin M, Wolf AP. Scintigraphy with positron-emitting compounds. 1. C-11 labeled thymidine and thymidylate. Int J Nucl Med Biol 1978; 5: 61-69.
17. Goethals P, Lameire N, van Eijkeren M, Kesteloot D, Thierens H, Dams R. [Methyl-carbon-11]thymidine for in vivo measurement of cell proliferation. J Nucl Med 1996; 37: 1048-1052.
18. 11C activity after injection of [methyl-carbon-11]thymidine in Wistar rats. J Nucl Med 1999; 40: 491-496.
19. Pomper MG, Constantinides CD, Barker PB, et al. Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [C-11-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol 2002; 9: 398-409.
20. 11C]-Thymidine PET scan in non-Hodgkin lymphoma. Eur J Nucl Med 1992; 8: 693.
21. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39: 1757-1762.
22. 11C-thymidine activity in human head and neck tumours using positron emission tomography. Acta Oncologica 1992; 31: 539-543.
23. 11C]thymidine. Br J Radiol 1994; 67: 292-295.
24. Vander Borght T, Pauwels S, Lambotte L, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994; 35: 974-982.
25. Eary J, Mankoff DA, Spence AM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999; 59: 615-621.
26. De Reuck J, Santens P, Goethals P, et al. [Methyl-C-11] thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurologica Belgica 1999; 99: 118-125.
27. Edgren M, Westlin JE, Ahlstrom H, et al. Positron emission tomography in the management of metastatic renal cell carcinoma. Antibody Immunoconjugates and Radiopharmaceuticals 1995; 8: 215-226.
28. Young H, Brock C, Wells P, Price P. Monitoring response to treatment in the development of anti-cancer drugs using positron emission tomography. Drug Information Journal 1999; 33: 237-244.
29. Grierson JR, Vesselle H, Hofstrand P, Chin L, Rasey JS. Comparative uptake and cell cycle measurements with [18F]FLT vs. [3H]thymidine in mammalian tumor cells. J Nucl Med 1998; 39(Suppl.): 229P-230P.
30. Rasey JS, Grierson JR. 3′deoxy-3′-[F-18]fluorothymidine (FLT) predicts changes in cell proliferation. J Nucl Med 1999; 40(Suppl.): 25P.
31. Toyohara J, Kato-Azuma M, Waki A, et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with thymidine, arabinothymidine and FDG, and cell analysis in 22 asynchronously growing tumor cell lines. J Nucl Med 2000; 42: 83P.
32. 18F]FLT and positron emission tomography. Nature Med 1998; 4: 1334-1336.
33. 18F]FLT: a portrait of a proliferation marker. Eur J Nucl Med 2002; 29: 165-169.
34. Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[F-18]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62: 3331-3334.
35. Ryser JE, Blauenstein P, Remy N, et al. [Br-76]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice. Nucl Med Biol 1999; 26: 673-679.
36. 76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. J Nucl Med 2000; 41: 1746-4752.
37. Lu L, Bergstrom M, Fasth KJ, Wu F, Eriksson B, Langstrom B. Elimination of nonspecific radioactivity from [Br-76]bromide in PET study with [Br-76]bromodeoxyuridine. Nucl Med Biol 1999; 26: 795-802.
38. Gardelle O, Roelcke U, Vontobel P, et al. [Br-76]bromodeoxyuridine PET in tumor-bearing animals. Nucl Med Biol 2001; 28: 51-57.
39. Bergström M, Lu L, Fasth KJ, et al. in vitro animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J Nucl Med 1998; 39: 1273-1279.
40. Gudjonsson O, Bergstrom M, Kristjansson S, et al. Analysis of Br-76-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. Nucl Med Biol 2001; 28: 59-65.
41. Boni R, Blauenstein P, Dummer R, von Schulthess GK, Schubiger PA, Steinert HC. Non-invasive assessment of tumour cell proliferation with positron emission tomography and [Br-76]bromodeoxyuridine. Melanoma Res 1999; 9: 569-573.
42. Goethals P, Lodewyck W, Van Eijkeren M, Dams R. Radioiodination of 2′deoxyuridine-preparation and preliminary evaluation in tumor-bearing rats. Appl Radiat Isotop 1994; 45: 149-153.
43. Kassis A, Adelstein SJ. Preclinical animal studies with radioiododeoxyuridine. J Nucl Med 1996; 37: 10S-12S.
44. Tjuvajev J, Muraki A, Ginos J, et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 1993; 34: 1152-1162.
45. Tjuvajev JG, Macapinlac HA, Daghighian F, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 1994; 35: 1407-1417.
46. Blasberg RG, Roelcke U, Weinreich R, et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 2000; 60: 624-635.
47. 123I]iodo-2′-dexoyuridine in patients with liver metastases from colorectal cancer. J Nucl Med 1996; 37: 22S-25S.
48. Sato K, Kameyama M, Ishiwata K, Katakura R, Yoshimoto T. Metabolic changes of glioma following chemotherapy and experimental study using 4 PET tracers. J Neuro-oncol 1992; 14: 81-89.
49. 18F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. Cancer Res 2001; 61: 3853-3857.